Skip to main content
. Author manuscript; available in PMC: 2022 Jul 7.
Published in final edited form as: Alzheimers Dement. 2019 Aug 6;15(9):1218–1228. doi: 10.1016/j.jalz.2019.04.011

Table 1.

Demographics AD-CBS and Controls

p-values

AD-AS n=42 AD-CBS n=43 CBD-CBS n=15 AD-AS vs AD-CBS AD-AS vs CBD-CBS AD-CBS vs CBD-CBS

Clinical features

Sex, male (%) 18 (43%) 17 (40%) 10 (63%)
Age at onset, years 63 (57,73) 61 (55,69) 64 (55,69)
Age at death, years 73 (67, 78) 70 (64,77) 71 (62, 77)
Disease duration 9 (7, 11) 9 (7, 1) 7 (5, 8) 0.05 0.02

Neuropathologic features

Brain weight 960 (920, 1070) 980 (860, 1060) 1160 (1040, 1295) <0.001 <0.001
Braak stage VI VI II-III (I, III) <0.001 <0.001
Thal phase 5 5 1 (0, 3) <0.001 <0.001
TDP-43 12/42 (28%) 7/43 (16%) 2/15 (13%) 0.008
Amygdala Lewy bodies 6 5 none

Regions of cortical atrophy at autopsy

Superior frontal gyrus 0 (0%) 4 (10%) 6 (40%) 0.05 <0.001 0.01
Paracentral lobule 2 (5%) 9 (22%) 2 (13%) 0.03
Temporal, anterior 8 (21%) 1 (2%) 0 (0%) 0.01
Parietal 9 (23%) 10 (24%) 1 (7%)
Occipital 13 (33%) 19 (43%) 3 (20%) 0.05

All variables are analyzed with Kruskal-Wallis ANOVA on Ranks and displayed as median (25th and 75th range), unless otherwise noted. Post hoc pairwise comparisons were performed with Mann-Whitney rank sum test. Only statistically significant p-values are shown.